Exelixis, Inc. (EXEL) vs Genmab A/S Sponsored ADR (GMAB)
- Exelixis, Inc. EXEL 62.11 −1.15%
- Genmab A/S Sponsored ADR GMAB 37.00 −2.17%
Exelixis, Inc. and Genmab A/S Sponsored ADR are both Biotechnology companies. Genmab A/S Sponsored ADR is the larger, with a market value of $22.6B against $15.6B — 1.5× the size. Exelixis, Inc. trades at the lower P/E: 18.8× against 29.1×. Genmab A/S Sponsored ADR grew revenue faster over the last twelve months: 22.3% against 9.23%. Exelixis, Inc. has the higher net margin (35.3% vs 19.1%) and the higher return on invested capital (60.5% vs 6.99%). Across the 21 metrics below, Exelixis, Inc. leads on 17 and Genmab A/S Sponsored ADR on 4.
Valuation
Profitability
| Metric | EXEL | GMAB | Biotechnology median |
|---|---|---|---|
| Gross margin | 96.48% | 93.03% | 65.16% |
| Operating margin | 39.88% | 25.95% | 0.00% |
| Net margin | 35.33% | 19.08% | 0.00% |
| Free cash flow margin | 47.55% | (153.64%) | 0.00% |
| Return on equity | 44.39% | 14.00% | (56.36%) |
| Return on assets | 33.28% | 8.30% | (48.04%) |
| Return on invested capital | 60.45% | 6.99% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack